Head-To-Head Analysis: eXoZymes (NASDAQ:EXOZ) & Curis (NASDAQ:CRIS)

eXoZymes (NASDAQ:EXOZ) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Insider & Institutional Ownership

30.0% of Curis shares are held by institutional investors. 72.4% of eXoZymes shares are held by company insiders. Comparatively, 5.4% of Curis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

eXoZymes has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.02, suggesting that its stock price is 202% more volatile than the S&P 500.

Profitability

This table compares eXoZymes and Curis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-104.58%	-79.55%
Curis	-313.79%	N/A	-106.37%

Earnings & Valuation

This table compares eXoZymes and Curis”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70,000.00	850.80	-$5.86 million	($0.77)	-9.21
Curis	$10.91 million	1.30	-$43.39 million	($3.67)	-0.28

eXoZymes has higher earnings, but lower revenue than Curis. eXoZymes is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for eXoZymes and Curis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1	0	0	0	1.00
Curis	1	0	1	0	2.00

Curis has a consensus price target of $17.00, indicating a potential upside of 1,550.49%. Given Curis’ stronger consensus rating and higher possible upside, analysts plainly believe Curis is more favorable than eXoZymes.

Summary

Curis beats eXoZymes on 8 of the 14 factors compared between the two stocks.

About eXoZymes

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

About Curis

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.